Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-HBED-CC PET/MRI vs MRI in Prostate Cancer
NCT03439033Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2018
- Primary completion
- May 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Started Apr 2018; status: terminated.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03439033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439033.